Growth inhibitory effect of 4-phenyl butyric acid on human gastric cancer cells is associated with cell cycle arrest

World Journal of Gastroenterology

Volumn 18, Issue 1, 2012, Pages 79-83

  Li, Long Zhu ^a   Deng, Hong Xia ^a   Lou, Wen Zhu ^a   Sun, Xue Yan ^a   Song, Meng Wan ^a   Tao, Jing ^a   Xiao, Bing Xiu ^a   Guo, Jun Ming ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

4 phenyl butyric acid; Anticancer effect; Cell cycle; Gastric carcinoma; Histone deacetylase inhibitor; Mgc 803; Sgc 7901

Indexed keywords

4 PHENYLBUTYRIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; STOMACH CANCER;

EID: 84862923920     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i1.79     Document Type: Article

References (30)

1. Spotswood HT, Turner BM. An increasingly complex code. J Clin Invest 2002; 110: 577-582
2. Turner BM. Cellular memory and the histone code. Cell 2002; 111: 285-291
3. Gray SG, Teh BT. Histone acetylation/deacetylation and cancer: an "open" and "shut" case? Curr Mol Med 2001; 1: 401-429
4. Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y, Suzuki H, Yawata A, Kusano M, Fujita M, Hosokawa M, Yanagihara K, Tokino T, Imai K. DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer 2002; 86: 1817-1823
5. Zhao X, Yang W, Shi C, Ma W, Liu J, Wang Y, Jiang G. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells. Tumour Biol 2011; 32: 335-346
6. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepa-tol 2009; 24: 652-657
7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
8. Vogiatzi P, Vindigni C, Roviello F, Renieri A, Giordano A. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol 2007; 211: 287-295
9. Bhalla K, List A. Histone deacetylase inhibitors in myelo-dysplastic syndrome. Best Pract Res Clin Haematol 2004; 17: 595-611
10. Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol 2005; 7: 177-182
11. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fbrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157: 484-490
12. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW. Phen-ylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996; 2: 379-387
13. Miller SJ. Cellular and physiological effects of short-chain fatty acids. Mini Rev Med Chem 2004; 4: 839-845
14. de Almeida SF, Picarote G, Fleming JV, Carmo-Fonseca M, Azevedo JE, de Sousa M. Chemical chaperones reduce endo-plasmic reticulum stress and prevent mutant HFE aggregate formation. J Biol Chem 2007; 282: 27905-27912
15. Kubota K, Niinuma Y, Kaneko M, Okuma Y, Sugai M, Omu-ra T, Uesugi M, Uehara T, Hosoi T, Nomura Y. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J Neurochem 2006; 97: 1259-1268
16. Li XN, Parikh S, Shu Q, Jung HL, Chow CW, Perlaky L, Leung HC, Su J, Blaney S, Lau CC. Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res 2004; 10: 1150-1159
17. Feinman R, Clarke KO, Harrison LE. Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kap-paB IN HT-29 colon cancer cells. Cancer Chemother Pharmacol 2002; 49: 27-34
18. Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P, Ekström TJ. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 2003; 22: 579-588
19. Glozak MA, Seto E. Histone deacetylases and cancer. Onco-gene 2007; 26: 5420-5432
20. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009; 625: 131-142
21. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692
22. Napieralski R, Ott K, Kremer M, Becker K, Boulesteix AL, Lordick F, Siewert JR, Höfler H, Keller G. Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features. Clin Cancer Res 2007; 13: 5095-5102
23. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxic-ity to anticancer drugs targeting DNA. Cancer Res 2003; 63: 7291-7300
24. Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, Yu MH. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 2008; 99: 1218-1226
25. Davies NP, Hardman LC, Murray V. The effect of chromatin structure on cisplatin damage in intact human cells. Nucleic Acids Res 2000; 28: 2954-2958
26. Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 2009; 15: 3163-3171
27. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE, Gschwend JE. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004; 90: 535-541
28. Miao Y, Xiao B, Jiang Z, Guo Y, Mao F, Zhao J, Huang X, Guo J. Growth inhibition and cell-cycle arrest of human gastric cancer cells by Lycium barbarum polysaccharide. Med Oncol 2010; 27: 785-790
29. Mendoza N, Fong S, Marsters J, Koeppen H, Schwall R, Wickramasinghe D. Selective cyclin-dependent kinase 2/cy-clin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res 2003; 63: 1020-1024
30. van den Heuvel S, Harlow E. Distinct roles for cyclin-depen-dent kinases in cell cycle control. Science 1993; 262: 2050-2054